|
ИСТИНА |
Войти в систему Регистрация |
Интеллектуальная Система Тематического Исследования НАукометрических данных |
||
ENCEPHALOPATHY AND HYPERLACTATEMIA AS A COMPLICATION OF 5-FLUOROURACIL TREATMENTстатья
Информация о цитировании статьи получена из
Scopus
Дата последнего поиска статьи во внешних источниках: 8 апреля 2022 г.
- Авторы: Kurmukov I.A., Yunayev G.S., Prosvirnov A.A., Borovkova N.B., Kashiya Sh R.
- Журнал: Siberian journal of oncology
- Том: 18
- Номер: 5
- Год издания: 2019
- Первая страница: 74
- Последняя страница: 79
- DOI: 10.21294/1814-4861-2019-18-5-74-79
- Аннотация: Background. there is a wide spectrum of metabolic and toxic disorders that can cause acute encephalopathy in cancer patients. In routine clinical practice, hypoglycemia, vitamin B1 (thiamine) deficit, fulminant liver failure, uremia, severe hypo- and hypernatremia should be primarily excluded. central neurotoxicity associated with hyperammonemia in patients receiving 5-fluorouracil (5-Fu) and oral fluoropyrimidines should be considered in differential diagnosis. In this case, the analysis of the blood acid-base status and the detection of B-type hyperlactatemia can facilitate the diagnosis of the cause of encephalopathy. Case description. We present two cases of hyperlactatemia and encephalopathy in stage IV cancer patients with continuous infusion of 5-Fu via a portable infusion pump. Conclusion. Diagnosis of the frequent fluoropyrimidin-related adverse effects, such as myelosuppression, anorexia, diarrhea, mucositis, and palm-plantar syndrome, are routine and mastered by an oncologist at the very beginning of his/her professional activity. specific fluoropyrimidine-related encephalopathy or hyperlactatemia are difficult to suspect and recognize. We hope our description will be useful to prevent possible diagnostic errors.
- Добавил в систему: Юнаев Григорий Сергеевич